In vivo bioluminescent imaging of α-fetoprotein-producing hepatocellular carcinoma in the diethylnitrosamine-treated mouse using recombinant adenoviral vector

Journal of Gene Medicine

Volumn 14, Issue 8, 2012, Pages 513-520

  Kim, Kwang Il ^a   Park, Ju Hui ^a   Lee, Yong Jin ^a   Lee, Tae Sup ^a   Park, Jae Jun ^a   Song, Inho ^a   Nahm, Sang Soep ^c   Cheon, Gi Jeong ^a   Lim, Sang Moo ^a   Chung, June Key ^b   Kang, Joo Hyun ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Konkuk University   (South Korea)

Author keywords

fetoprotein promoter; Adenovirus; Bioluminescent imaging; Diethylnitrosamine; Hepatocellular carcinoma

Indexed keywords

ADENOVIRUS VECTOR; ALPHA FETOPROTEIN; DIETHYLNITROSAMINE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; ENZYME ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADENOVIRIDAE; ALPHA-FETOPROTEINS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DIETHYLNITROSAMINE; FEMALE; GENE EXPRESSION; GENES, REPORTER; GENETIC VECTORS; HUMANS; LIVER NEOPLASMS; LUCIFERASES, FIREFLY; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MOLECULAR IMAGING; NEOPLASM TRANSPLANTATION; RATS; WHOLE BODY IMAGING;

EID: 84865441383     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.2648     Document Type: Article

References (34)

1. Levin B, Amos C. Therapy of unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1294-1296.
2. Welzel TM, Graubard BI, Zeuzem S, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. Hepatology 2011; 54: 463-471.
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-1917.
4. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15: 225-236.
5. Farmer DG, Busuttil RW. The role of multimodal therapy in the treatment of hepatocellular carcinoma. Cancer 1994; 73: 2669-2670.
6. Venook AP. Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994; 12: 1323-1334.
7. El-Serag HB, Marrero JA, Rudolph L, et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008; 134: 1752-1763.
8. Rodriguez MM, Ryu SM, Qian C, et al. Immunotherapy of murine hepatocellular carcinoma by alpha-fetoprotein DNA vaccination combined with adenovirus-mediated chemokine and cytokine expression. Hum Gene Ther 2008; 19: 753-759.
9. Okimoto T, Yahata H, Itou H, et al. Safety and growth suppressive effect of intra-hepatic arterial injection of AdCMV-p53 combined with CDDP to rat liver metastatic tumours. J Exp Clin Cancer Res 2003; 22: 399-406.
10. Bilbao R, Gerolami R, Bralet MP, et al. Transduction efficacy, antitumoural effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Ther 2000; 7: 657-662.
11. Havlik R, Jiao LR, Nicholls J, et al. Gene therapy for liver metastases. Semin Oncol 2002; 29: 202-208.
12. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 2007; 9: 833-842.
13. Yu Y, Annala AJ, Barrio JR, et al. Quantification of target gene expression by imaging reporter gene expression in living animals. Nat Med 2000; 6: 933-937.
14. Park JH, Kim KI, Lee YJ, et al. Non-invasive monitoring of hepatocellular carcinoma in transgenic mouse with bioluminescent imaging. Cancer Lett 2011; 310: 53-60.
15. Huard J, Lochmuller H, Acsadi G, et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther 1995; 2: 107-115.
16. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-308.
17. Sa Cunha A, Bonte E, Dubois S, et al. Inhibition of rat hepatocellular carcinoma tumour growth after multiple infusions of recombinant Ad.AFPtk followed by ganciclovir treatment. J Hepatol 2002; 37: 222-230.
18. Miao J, Chen GG, Chun SY, et al. Adenovirus-mediated tBid overexpression results in therapeutic effects on p53-resistant hepatocellular carcinoma. Int J Cancer 2006; 119: 1985-93.
19. Willhauck MJ, Sharif Samani BR, Klutz K, et al. Alpha-fetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 2008; 15: 214-223.
20. Kim KI, Kang JH, Chung JK, et al. Doxorubicin enhances the expression of transgene under control of the CMV promoter in anaplastic thyroid carcinoma cells. J Nucl Med 2007; 48: 1553-1561.
21. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464-7472.
22. Takahashi M, Sato T, Sagawa T, et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumour. Mol Ther 2002; 5: 627-634.
23. Sagawa T, Takahashi M, Sato T, et al. Prolonged survival of mice with multiple liver metastases of human colon cancer by intravenous administration of replicable E1B-55K-deleted adenovirus with E1A expressed by CEA promoter. Mol Ther 2004; 10: 1043-1050.
24. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, et al. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583.
25. Okada Y, Okada N, Mizuguchi H, et al. Transcriptional targeting of RGD fiber-mutant adenovirus vectors can improve the safety of suicide gene therapy for murine melanoma. Cancer Gene Ther 2005; 12: 608-616.
26. Ali M, Lemoine NR, Ring CJ. The use of DNA viruses as vectors for gene therapy. Gene Ther 1994; 1: 367-384.
27. Chen L, Altmann A, Mier W, et al. Radioiodine therapy of hepatoma using targeted transfer of the human sodium/iodide symporter gene. J Nucl Med 2006; 47: 854-862.
28. Faivre J, Clerc J, Gerolami R, et al. Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats. Cancer Res 2004; 64: 8045-8051.
29. Scholz IV, Cengic N, Baker CH, et al. Radioiodine therapy of colon cancer following tissue-specific sodium iodide symporter gene transfer. Gene Ther 2005; 12: 272-280.
30. Blechacz B, Splinter PL, Greiner S, et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 2006; 44: 1465-1477.
31. Ahn BC, Ronald JA, Kim YI, et al. Potent, tumour-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector. Gene Ther 2011; 18: 606-612.
32. Kishimoto H, Zhao M, Hayashi K, et al. In vivo internal tumour illumination by telomerase-dependent adenoviral GFP for precise surgical navigation. Proc Natl Acad Sci USA 2009; 106: 14514-14517.
33. Kishimoto H, Urata Y, Tanaka N, et al. Selective metastatic tumour labelling with green fluorescent protein and killing by systemic administration of telomerase-dependent adenoviruses. Mol Cancer Ther 2009; 8: 3001-3008.
34. Kishimoto H, Aki R, Urata Y, et al. Tumour-selective, adenoviral-mediated GFP genetic labelling of human cancer in the live mouse reports future recurrence after resection. Cell Cycle 2011; 10: 2737-2741.